[ad_1]
SAN FRANCISCO and UNITED KINGDOM, December 1, 2020 (GLOBE NEWSWIRE) – iRhythm Technologies (NASDAQ: IRTC), a leading digital healthcare solutions company focused on advancing cardiac care, announced today that it is the first technology to go through a new digital health technology pilot project, which resulted in a successful recommendation for adoption by the National Institute for Health and Care Excellence (NICE).
IRhythm’s Zio XT Service, a patient-friendly outpatient heart monitor supported by deep learning algorithms, has been evaluated as part of NICE’s first pilot project to evaluate digital health technologies. Zio XT has been positively recommended by NICE as an option for people with suspected cardiac arrhythmias who would benefit from ECG monitoring for more than 24 hours.
Released today, the guide concluded that Zio XT is comfortable and easy to wear, with improved patient compliance and better diagnostic yield (a measure of how many people with cardiac arrhythmias are diagnosed) than standard 24-hour Holter monitoring. Clinical evidence showed that patients preferred Zio XT over the current monitoring practice in the NHS, which usually involves the use of a continuous ECG monitor, such as the 24-hour Holter monitor. Estimates also suggest that using Zio XT is likely to save costs or have the same cost as 24-hour Holter monitoring.
Commenting on the news, Justin Hall, GM and VP EMEA of iRhythm said, “We are delighted that Uncle has received such positive guidance from NICE in this first of its kind assessment, especially at such a critical time. During the COVID-19 pandemic we have seen a number of heart patients avoid hospitals and suffer in silence, even in serious conditions such as strokes. This has led to a backlog of patients in need of treatment, putting further pressure on medical staff and services. “
“Fortunately, services like Uncle can help alleviate this backlog by offering clinically validated services remotely. Patients are not required to expose themselves to high-risk hospital environments, while staff can still offer the same level of ongoing care. therefore, that patients have access to these technologies and that doctors are able to implement them quickly and easily. “
The guide, which evaluates new and innovative medical devices and diagnostic systems, aims to help NHS people make efficient, cost-effective and consistent decisions about adopting new medical technologies. Positive guidance from NICE Medical Technologies opens the door for future Zio service support through the MedTech Funding Mandate, which aims to accelerate the adoption of proven, affordable innovations as part of the NHS Long Term Plan.
IRhythm’s positive recommendation from the NICE digital health pilot project builds on the company’s recent win of the UK Government’s AI in Health and Care award, in which iRhythm will use the funding to evaluate its Zio service at selected NHS sites across the UK. During the three-year program, clinical, path and economic outcomes will be monitored and evaluated in order to inform any future commissioning decisions on the adoption of Zio within the NHS.
About iRhythm Technologies, Inc.
iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are diagnosed clinically. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically usable information. The company believes that improvements in arrhythmia detection and characterization have the potential to change the clinical management of patients.
Average Contacts:
Ellie Stansfield
Hotwire for iRhythm Technologies
[email protected]
Saige Smith
HighwirePR for iRhythm Technologies
[email protected]
Investor Contact for relations:
Leigh Salvo
Gilmartin Group
[email protected]
.
[ad_2]
Source link
